Studies in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death.
Contra-indicated in patients with asthma without use of a long-term asthma control medication.
- TRADE NAME: Brovana (Sunovion)
- INDICATIONS: Chronic obstructive pulmonary disease including chronic bronchitis and emphysema
- CLASS: Beta-2 adrenergic agonist, Bronchodilator
- HALF-LIFE: 26 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Beta blockers, MAO inhibitors, Tricyclic antidepressants
- See adverse reactions attributed to class:
ASTHMA-RELATED DEATH
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of arformoterol in the Informa Healthcare journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
